Influence of blood glucose fluctuations on chemotherapy efficacy and safety in type 2 diabetes mellitus patients complicated with lung carcinoma

Figure 1 Comparison of blood glucose levels after chemotherapy. A: Fasting blood glucose level of the two groups after chemotherapy; B: 2-h postprandial blood glucose level of the two groups after chemotherapy. ^aP < 0.05, ^bP < 0.001.

Figure 2 Comparison of serum inflammatory cytokines after chemotherapy. A: Tumor necrosis factor-α level of the two groups after chemotherapy; B: Interleukin-6 Level of the two groups after chemotherapy; C: High-sensitivity C-reactive protein level of the two groups after chemotherapy. ^bP < 0.001. TNF-α: Tumor necrosis factor-α; IL-6: Interleukin-6; hs-CRP: High-sensitivity C-reactive protein.

Figure 3 Correlation between mean amplitude of glycemic excursions and tumor markers in all patients. A: Correlation of mean amplitude of glycemic excursions (MAGE) with carbohydrate antigen 19-9 (CA19-9) level in all patients; B: Correlation of MAGE with CA125 level in all patients; C: Correlation of MAGE with carcinoembryonic antigen level in all patients; D: Correlation of MAGE with neuron-specific enolase level in all patients; E: Correlation of MAGE with cytokeratin 19 level in all patients. MAGE: Mean amplitude of glycemic excursions; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; NSE: Neuron-specific enolase; CYFRA21-1: Cytokeratin 19.